XM does not provide services to residents of the United States of America.

Indian shares log best weekly winning streak since 2010



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares log best weekly winning streak since 2010</title></head><body>

Updates to close

By Bharath Rajeswaran

BENGALURU, July 26 (Reuters) - Information technology stocks lifted Indian benchmark indexes on Friday as an improvement in economic growth in the U.S., a key market for the sector, boosted sentiment.

Both the benchmarks added 1.24% and 0.9% for the week, posting eighth week of gains.

The NSE Nifty 50 .NSEI rose 1.76% to 24,834.85, while the S&P BSE Sensex .BSESN gained 1.62% to 81,332.72, logging their best session in seven weeks.

The Nifty also hit a record high in the final minute of the trading session.

Both Nifty and Sensex had logged losses for the last five sessions, weighed down by weaker-than-expected results from Reliance Industries RELI.NS, Wipro WIPR.NS, Bajaj Finance BJFN.NS, Axis Bank AXBK.NS and Nestle NEST.NS.

The union budget on Tuesday, in which tax hikes on capital gains in equity investments and derivatives trading were announced, also had a negative, but short-term impact on the market, analysts said.

Allthe 13 major sectors advanced, on the day.

Information technology stocks .NIFTYIT rose 2.3%, afterdata showed that the U.S. economy grew faster than expected in the second quarter.

Improving growth outlook in the U.S. helps Indian IT companies, which earn a significant share of their revenue from the country.

Investors await the U.S. personal consumption expenditures data - the Federal Reserve's preferred gauge of inflation - due after the closing bell, to confirm bets of a rate cut in September.

"Most IT companies have indicated green shoots in discretionary spends and large verticals like banking and financial services, which is also aiding investor interest in the sector," said Meeta Shetty, fund manager at Tata Asset Management.

Metal index .NIFTYMET gained 3%. It had shed 1.3% in the previous session on demand concerns in top consumer China.

Drug maker Cipla CIPL.NS gained 5%, powering pharma index .NIPHARM 2.3% higher, afterposting first-quarter profit above expectations, aided by higher sales.

The broader, more domestically focussed small- .NIFSMCP100 and mid-caps .NIFMDCP100 rose 1% and 1.8%, on the day.



($1 = 83.7330 Indian rupees)


Weekly performance of India's key stock indexes https://reut.rs/4djlMaW

Weekly performance of India's Nifty 50 stocks https://reut.rs/3zVevjj

India's Nifty 50 logs longest weekly winning streak in over 14 years https://reut.rs/3WCoaUP


Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sherry Jacob-Phillips and Nivedita Bhattacharjee

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.